The Institute of Cancer Research
NICE’s second Zytiga rejection ‘shows need for flexible pricing models’
Phil Taylor
Johnson & Johnson, NICE, Oncology, Prostate cancer, The Institute of Cancer Research, Zytiga
0 Comment
X
NICE’s second Zytiga rejection ‘shows need for flexible pricing models’
https://pharmaphorum.com/news/nice-second-zytiga-rejection-shows-need-for-flexible-pricing-models/